Neuronal Ca2+ dyshomeostasis in Huntington disease

Prion

Volumn 7, Issue 1, 2013, Pages 76-84

  Giacomello, Marta ^a   Oliveros, Juan C ^b   Naranjo, Jose R ^b,c   Carafoli, Ernesto ^d  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^d VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

Calcium; Huntington; Huntington disease; Mitochondria; Transcription

Indexed keywords

CALCIUM ION; CALCIUM;

CALCIUM BALANCE; CELL DEATH; CELL SURVIVAL; CONFERENCE PAPER; DISEASE MODEL; EXPERIMENTAL MOUSE; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; INTRACELLULAR SPACE; MOLECULAR MECHANICS; NONHUMAN; ANIMAL; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUNTINGTON; METABOLISM; MITOCHONDRION; NERVE CELL; PATHOLOGY; REVIEW; TRANSCRIPTION;

CALCIUM; HUNTINGTON; HUNTINGTON DISEASE; MITOCHONDRIA; TRANSCRIPTION;

ANIMALS; CALCIUM; GENE EXPRESSION REGULATION; HUMANS; HUNTINGTON DISEASE; MITOCHONDRIA; NEURONS; TRANSCRIPTION, GENETIC;

EID: 84874612390     PISSN: 19336896     EISSN: 1933690X     Source Type: Journal    
DOI: 10.4161/pri.23581     Document Type: Conference Paper

References (54)

1. Arrasate M, Finkbeiner S. Protein aggregates in Huntington's disease. Exp Neurol 2012; 238:1-11; PMID:22200539.
2. Nagaoka U, Kim K, Jana NR, Doi H, Maruyama M, Mitsui K, et al. Increased expression of p62 in expanded polyglutamine-expressing cells and its association with polyglutamine inclusions. J Neurochem 2004; 91:57-68; PMID:15379887.
3. Valenza M, Rigamonti D, Goffredo D, Zuccato C, Fenu S, Jamot L, et al. Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J Neurosci 2005; 25:9932-9; PMID:16251441.
4. Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 2010; 90:905-81; PMID:20664076.
5. Bertoni A, Giuliano P, Galgani M, Rotoli D, Ulianich L, Adornetto A, et al. Early and late events induced by polyQ-expanded proteins: identification of a common pathogenic property of polYQ-expanded proteins. J Biol Chem 2011; 286:4727-41; PMID:21115499.
6. Hands S, Sajjad MU, Newton MJ, Wyttenbach A. In vitro and in vivo aggregation of a fragment of huntingtin protein directly causes free radical production. J Biol Chem 2011; 286:44512-20; PMID:21984825.
7. Tabrizi SJ, Workman J, Hart PE, Mangiarini L, Mahal A, Bates G, et al. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann Neurol 2000; 47:80-6; PMID:10632104.
8. Arenas J, Campos Y, Ribacoba R, Martín MA, Rubio JC, Ablanedo P, et al. Complex I defect in muscle from patients with Huntington's disease. Ann Neurol 1998; 43:397-400; PMID:9506560.
9. Costa V, Giacomello M, Hudec R, Lopreiato R, Ermak G, Lim D, et al. Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli. EMBO Mol Med 2010; 2:490-503; PMID:21069748.
10. Giacomello M, Hudec R, Lopreiato R. Huntington's disease, calcium, and mitochondria. Biofactors 2011; 37:206-18; PMID:21674644.
11. Saris NE, Carafoli E. A historical review of cellular calcium handling, with emphasis on mitochondria. Biochemistry (Mosc) 2005; 70:187-94; PMID:15807658.
12. Naranjo JR, Mellström B. Ca2+-dependent transcriptional control of Ca2+ homeostasis. J Biol Chem 2012; 287:31674-80; PMID:22822058.
13. Carafoli E, Tiozzo R, Lugli G, Crovetti F, Kratzing C. The release of calcium from heart mitochondria by sodium. J Mol Cell Cardiol 1974; 6:361-71; PMID:4855051.
14. Giacomello M, Drago I, Pizzo P, Pozzan T. Mitochondrial Ca2+ as a key regulator of cell life and death. Cell Death Differ 2007; 14:1267-74; PMID:17431419.
15. Brouillet E, Hantraye P. Effects of chronic MPTP and 3-nitropropionic acid in nonhuman primates. Curr Opin Neurol 1995; 8:469-73; PMID:8845934.
16. Tang TS, Tu H, Chan EY, Maximov A, Wang Z, Wellington CL, et al. Huntingtin and huntingtinassociated protein 1 influence neuronal calcium signaling mediated by inositol-(1, 4, 5) triphosphate receptor type 1. Neuron 2003; 39:227-39; PMID:12873381.
17. Luthi-Carter R, Hanson SA, Strand AD, Bergstrom DA, Chun W, Peters NL, et al. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum Mol Genet 2002; 11:1911-26; PMID:12165554.
18. Hansson O, Guatteo E, Mercuri NB, Bernardi G, Li XJ, Castilho RF, et al. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. Eur J Neurosci 2001; 14:1492-504; PMID:11722611.
19. Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, et al. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 2002; 5:731-6; PMID:12089530.
20. Choo YS, Johnson GV, MacDonald M, Detloff PJ, Lesort M. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum Mol Genet 2004; 13:1407-20; PMID:15163634.
21. Milakovic T, Quintanilla RA, Johnson GV. Mutant huntingtin expression induces mitochondrial calcium handling defects in clonal striatal cells: functional consequences. J Biol Chem 2006; 281:34785-95; PMID:16973623.
22. Brustovetsky N, LaFrance R, Purl KJ, Brustovetsky T, Keene CD, Low WC, et al. Age-dependent changes in the calcium sensitivity of striatal mitochondria in mouse models of Huntington's Disease. J Neurochem 2005; 93:1361-70; PMID:15935052.
23. Oliveira JM, Jekabsons MB, Chen S, Lin A, Rego AC, Gonçalves J, et al. Mitochondrial dysfunction in Huntington's disease: the bioenergetics of isolated and in situ mitochondria from transgenic mice. J Neurochem 2007; 101:241-9; PMID:17394466.
24. Zhang H, Das S, Li QZ, Dragatsis I, Repa J, Zeitlin S, et al. Elucidating a normal function of huntingtin by functional and microarray analysis of huntingtin-null mouse embryonic fibroblasts. BMC Neurosci 2008; 9:38; PMID:18412970.
25. Kipanyula MJ, Contreras L, Zampese E, Lazzari C, Wong AK, Pizzo P, et al. Ca2+ dysregulation in neurons from transgenic mice expressing mutant presenilin 2. Aging Cell 2012; 11:885-93; PMID:22805202.
26. Bauer PO, Hudec R, Ozaki S, Okuno M, Ebisui E, Mikoshiba K, et al. Genetic ablation and chemical inhibition of IP3R1 reduce mutant huntingtin aggregation. Biochem Biophys Res Commun 2011; 416:13-7; PMID:22056561.
27. Atwal RS, Xia J, Pinchev D, Taylor J, Epand RM, Truant R. Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. Hum Mol Genet 2007; 16:2600-15; PMID:17704510.
28. Benn CL, Landles C, Li H, Strand AD, Woodman B, Sathasivam K, et al. Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease. Hum Mol Genet 2005; 14:3065-78; PMID:16183657.
29. Cornett J, Cao F, Wang CE, Ross CA, Bates GP, Li SH, et al. Polyglutamine expansion of huntingtin impairs its nuclear export. Nat Genet 2005; 37:198-204; PMID:15654337.
30. Wu J, Shih HP, Vigont V, Hrdlicka L, Diggins L, Singh C, et al. Neuronal store-operated calcium entry pathway as a novel therapeutic target for Huntington's disease treatment. Chem Biol 2011; 18:777-93; PMID:21700213.
31. Swayne LA, Chen L, Hameed S, Barr W, Charlesworth E, Colicos MA, et al. Crosstalk between huntingtin and syntaxin 1A regulates N-type calcium channels. Mol Cell Neurosci 2005; 30:339-51; PMID:16162412.
32. Bao J, Sharp AH, Wagster MV, Becher M, Schilling G, Ross CA, et al. Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin. Proc Natl Acad Sci U S A 1996; 93:5037-42; PMID:8643525.
33. Kreutz MR, Naranjo JR, Koch KW, Schwaller B. The Neuronal Functions of EF-Hand Ca2+-Binding Proteins. [ì]. Front Mol Neurosci 2012; 5:92; PMID:22973191.
34. Dudek NL, Dai Y, Muma NA. Neuroprotective effects of calmodulin peptide 76-121aa: disruption of calmodulin binding to mutant huntingtin. Brain Pathol 2010; 20:176-89; PMID:19338577.
35. Dudek NL, Dai Y, Muma NA. Protective effects of interrupting the binding of calmodulin to mutant huntingtin. J Neuropathol Exp Neurol 2008; 67:355-65; PMID:18379433.
36. Dong G, Gross K, Qiao F, Ferguson J, Callegari EA, Rezvani K, et al. Calretinin interacts with huntingtin and reduces mutant huntingtin-caused cytotoxicity. J Neurochem 2012; 123:437-46; PMID:22891683.
37. Rockabrand E, Slepko N, Pantalone A, Nukala VN, Kazantsev A, Marsh JL, et al. The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Hum Mol Genet 2007; 16:61-77; PMID:17135277.
38. Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G, et al. Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet 2006; 15:965-77; PMID:16467349.
39. Seredenina T, Luthi-Carter R. What have we learned from gene expression profiles in Huntington's disease? Neurobiol Dis 2012; 45:83-98; PMID:21820514.
40. Savas JN, Makusky A, Ottosen S, Baillat D, Then F, Krainc D, et al. Huntington's disease protein contributes to RNA-mediated gene silencing through association with Argonaute and P bodies. Proc Natl Acad Sci U S A 2008; 105:10820-5; PMID:18669659.
41. Lee ST, Chu K, Im WS, Yoon HJ, Im JY, Park JE, et al. Altered microRNA regulation in Huntington's disease models. Exp Neurol 2011; 227:172-9; PMID:21035445.
42. Hogel M, Laprairie RB, Denovan-Wright EM. Promoters are differentially sensitive to N-terminal mutant huntingtin-mediated transcriptional repression. PLoS One 2012; 7:e41152; PMID:22815947.
43. Nucifora FC Jr., Sasaki M, Peters MF, Huang H, Cooper JK, Yamada M, et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 2001; 291:2423-8; PMID:11264541.
44. Mantamadiotis T, Lemberger T, Bleckmann SC, Kern H, Kretz O, Martin Villalba A, et al. Disruption of CREB function in brain leads to neurodegeneration. Nat Genet 2002; 31:47-54; PMID:11967539.
45. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006; 127:59-69; PMID:17018277.
46. Lin J, Wu PH, Tarr PT, Lindenberg KS, St-Pierre J, Zhang CY, et al. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 2004; 119:121-35; PMID:15454086.
47. Gambazzi L, Gokce O, Seredenina T, Katsyuba E, Runne H, Markram H, et al. Diminished activitydependent brain-derived neurotrophic factor expression underlies cortical neuron microcircuit hypoconnectivity resulting from exposure to mutant huntingtin fragments. J Pharmacol Exp Ther 2010; 335:13-22; PMID:20624994.
48. Zuccato C, Marullo M, Conforti P, MacDonald ME, Tartari M, Cattaneo E. Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease. Brain Pathol 2008; 18:225-38; PMID:18093249.
49. Ledo F, Kremer L, Mellström B, Naranjo JR. Ca2+- dependent block of CREB-CBP transcription by repressor DREAM. EMBO J 2002; 21:4583-92; PMID:12198160.
50. Savignac M, Pintado B, Gutierrez-Adan A, Palczewska M, Mellström B, Naranjo JR. Transcriptional repressor DREAM regulates T-lymphocyte proliferation and cytokine gene expression. EMBO J 2005; 24:3555-64; PMID:16177826.
51. Kashani AH, Qiu Z, Jurata L, Lee SK, Pfaff S, Goebbels S, et al. Calcium activation of the LMO4 transcription complex and its role in the patterning of thalamocortical connections. J Neurosci 2006; 26:8398-408; PMID:16899735.
52. Giacomello M, Drago I, Bortolozzi M, Scorzeto M, Gianelle A, Pizzo P, et al. Ca2+ hot spots on the mitochondrial surface are generated by Ca2+ mobilization from stores, but not by activation of storeoperated Ca2+ channels. Mol Cell 2010; 38:280-90; PMID:20417605.
53. Csordás G, Várnai P, Golenár T, Roy S, Purkins G, Schneider TG, et al. Imaging interorganelle contacts and local calcium dynamics at the ER-mitochondrial interface. Mol Cell 2010; 39:121-32; PMID:20603080.
54. Saeed AI, Bhagabati NK, Braisted JC, Liang W, Sharov V, Howe EA, et al. TM4 microarray software suite. Methods Enzymol 2006; 411:134-93; PMID:16939790.